BioCentury | Jan 30, 2021
Deals

Catabasis reboots with takeout of Xontogeny’s Quellis; plus Merck-Artiva, Lilly-Asahi, Medigene, Xuanzhu-Combio, Bellicum

Three months after its lone asset failed in Phase III testing, Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) is acquiring Xontogeny portfolio company Quellis Biosciences Inc. and  recapitalizing through a $110 million PIPE led by Xontogeny affiliate Perceptive Advisors....
BioCentury | Apr 25, 2020
Targets & Mechanisms

Trends to surf for at AACR 2020

While the abstracts for this year’s virtual AACR meeting won’t be available until Monday -- and most data won’t be presented until June -- key session titles, combined with an analysis of recent trends in...
BioCentury | Apr 8, 2020
Finance

Suzhou Ribo raises $66.3M for nucleic acid therapies

Four months after closing a RMB203 million ($28.8 million) series C round, Suzhou Ribo Life Science Co. Ltd. has raised an additional RMB470 million in a series C2 round to advance its RNAi and antisense...
BioCentury | Apr 2, 2020
Finance

Dynacure taps U.S. crossovers in €50M series C to fund orphan muscle disease studies

Dynacure expects its €50 million ($55.4 million) series C round to fund an ongoing trial of its lead program for myotubular and centronuclear myopathies in adults, as well as a planned pediatric study. Together, the...
BioCentury | Jan 18, 2020
Financial News

Define Ventures closes first digital health fund with $87M

Led by a former Kleiner Perkins partner, Define Ventures launched Monday with an $87 million first fund, which will invest in early stage digital health companies. Founder and Managing Partner Lynne Chou O'Keefe was a...
BioCentury | Jan 4, 2020
Finance

All’s well that ends well

Biotech companies across all market cap tiers posted big gains in the fourth quarter of 2019, with median changes ranging from 7-18%. 4Q19 growth was enough to erase prior quarter losses, putting all tiers in...
BioCentury | Jan 2, 2020
Politics & Policy

Drug price hikes would have been impossible under pending bipartisan legislation backed by White House, Democrats

The latest round of increases in the list prices of drugs highlights how pending bipartisan legislation could force biopharma companies to rethink their business models. In what has become a predictable biannual event, manufacturers announced...
BioCentury | Dec 21, 2019
Company News

Dec. 20 Company Quick Takes: Genmab partners with CureVac; plus pair of Biogen deals, Ionis, Akcea-Novartis, Paratek and J&J-Taris

CureVac, Genmab to develop RNA-encoded antibody Genmab A/S (NASDAQ:GMAB; CSE:GMAB) and CureVac AG have partnered to discover an mRNA-encoded antibody candidate to treat cancer. Genmab will pay $10 million up front and invest €20 million...
BioCentury | Nov 22, 2019
Finance

DigiTx focuses on data in evolving landscape of digital health investing

As one of the few digital therapeutics-focused investors, DigiTx is parsing opportunities in the rapidly expanding field by homing in on companies that use or generate patient data in innovative ways. DigiTx Partners was launched...
BioCentury | Oct 4, 2019
Finance

Biotech down again in 3Q19

Biotech stocks are continuing a downward trend, with all market cap tiers losing value in 3Q19, leading to a total quarterly loss of $88.8 billion. Companies valued at $1-$4.9 billion, $5-$9.9 billion and above $10...
Items per page:
1 - 10 of 607
BioCentury | Jan 30, 2021
Deals

Catabasis reboots with takeout of Xontogeny’s Quellis; plus Merck-Artiva, Lilly-Asahi, Medigene, Xuanzhu-Combio, Bellicum

Three months after its lone asset failed in Phase III testing, Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) is acquiring Xontogeny portfolio company Quellis Biosciences Inc. and  recapitalizing through a $110 million PIPE led by Xontogeny affiliate Perceptive Advisors....
BioCentury | Apr 25, 2020
Targets & Mechanisms

Trends to surf for at AACR 2020

While the abstracts for this year’s virtual AACR meeting won’t be available until Monday -- and most data won’t be presented until June -- key session titles, combined with an analysis of recent trends in...
BioCentury | Apr 8, 2020
Finance

Suzhou Ribo raises $66.3M for nucleic acid therapies

Four months after closing a RMB203 million ($28.8 million) series C round, Suzhou Ribo Life Science Co. Ltd. has raised an additional RMB470 million in a series C2 round to advance its RNAi and antisense...
BioCentury | Apr 2, 2020
Finance

Dynacure taps U.S. crossovers in €50M series C to fund orphan muscle disease studies

Dynacure expects its €50 million ($55.4 million) series C round to fund an ongoing trial of its lead program for myotubular and centronuclear myopathies in adults, as well as a planned pediatric study. Together, the...
BioCentury | Jan 18, 2020
Financial News

Define Ventures closes first digital health fund with $87M

Led by a former Kleiner Perkins partner, Define Ventures launched Monday with an $87 million first fund, which will invest in early stage digital health companies. Founder and Managing Partner Lynne Chou O'Keefe was a...
BioCentury | Jan 4, 2020
Finance

All’s well that ends well

Biotech companies across all market cap tiers posted big gains in the fourth quarter of 2019, with median changes ranging from 7-18%. 4Q19 growth was enough to erase prior quarter losses, putting all tiers in...
BioCentury | Jan 2, 2020
Politics & Policy

Drug price hikes would have been impossible under pending bipartisan legislation backed by White House, Democrats

The latest round of increases in the list prices of drugs highlights how pending bipartisan legislation could force biopharma companies to rethink their business models. In what has become a predictable biannual event, manufacturers announced...
BioCentury | Dec 21, 2019
Company News

Dec. 20 Company Quick Takes: Genmab partners with CureVac; plus pair of Biogen deals, Ionis, Akcea-Novartis, Paratek and J&J-Taris

CureVac, Genmab to develop RNA-encoded antibody Genmab A/S (NASDAQ:GMAB; CSE:GMAB) and CureVac AG have partnered to discover an mRNA-encoded antibody candidate to treat cancer. Genmab will pay $10 million up front and invest €20 million...
BioCentury | Nov 22, 2019
Finance

DigiTx focuses on data in evolving landscape of digital health investing

As one of the few digital therapeutics-focused investors, DigiTx is parsing opportunities in the rapidly expanding field by homing in on companies that use or generate patient data in innovative ways. DigiTx Partners was launched...
BioCentury | Oct 4, 2019
Finance

Biotech down again in 3Q19

Biotech stocks are continuing a downward trend, with all market cap tiers losing value in 3Q19, leading to a total quarterly loss of $88.8 billion. Companies valued at $1-$4.9 billion, $5-$9.9 billion and above $10...
Items per page:
1 - 10 of 607